Published on 01 January 2022
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
View DatasetIpsen
Description
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Citations (0)
No citations found
It looks like this dataset has no citations.
Mentions (0)
No mentions found
It looks like this dataset has not been mentioned in any sources.
Metrics Over Time
Publication Details
Subfield
Epidemiology
Field
Medicine
Domain
Health Sciences
Confidence Score
54%
Source
Scholar Data Model
Keywords
Conditions: Endocrine TumorsInterventions: lanreotide (Autogel formulation)Interventions: Placebo